HENDERSON, NV / ACCESSWIRE / January 4, 2019 / Biotech companies could be in store for a big 2019, and investors are starting to take notice. The stocks we are highlighting today all look poised for a big year.
One we like in particular, Delcath Systems, Inc. (DCTH), has one of the most impressive liver cancer treatments in development, is already in clinical trials, increased their revenue this past year, and just signed a deal with a projected value of up to $45 million. The stock is still a relative unknown, but when the street learns about this company it could go parabolic. Start your research on DCTH today.
Today we are highlighting: Delcath Systems, Inc. (DCTH), Novavax, Inc. (NASDAQ:NVAX), vTv Therapeutics, Inc. (VTVT), Cronos Group, Inc. (NASDAQ:CRON), and Viking Therapeutics, Inc. (NASDAQ:VKTX).
An interventional oncology company focused on treating liver cancers with some serious upside potential, Delcath Systems, Inc. (DCTH) (Market Cap: $2.404M, Share Price: $0.2557) has had quite a year. They announced their Phase 3 clinical trial, raised $7 million, increased revenue 20% Y/Y, and were published in European Radiology among several other milestones.
The company made major news today entering a licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac). The agreement has a projected value of up to $45 million over the first seven-year term and includes an optional five-year extension. Medac is a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases. The company has offices globally, worldwide partner agreements in over 90 countries, and approximately 1,200 employees.
This comes on the heels of an announcement about the independent Data Safety Monitoring Board (DSMB) of the Registration trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review of safety data for treated patients in the trial. This review was conducted on data collected from both the prior randomized protocol and the amended single-arm protocol for the FOCUS Trial. The DSMB again recommended continuation of the study without modification.
With news like this DCTH could make a major move in the coming sessions.
Novavax, Inc. (NVAX) (Market Cap: $781.014M, Share Price: $2.04) recently promoted Jill Hoyt to Senior Vice President of Human Resources and Biegie Lee to Vice President of Information Technology.
vTv Therapeutics, Inc. (VTVT) (Market Cap: $112.079M, Share Price: $2.58) came out with impressive third quarter numbers reporting a quarterly loss of $0.06 per share. Zacks estimated a loss of $0.15. This compares to loss of $0.38 per share a year ago.
Cronos Group, Inc. (CRON) (Market Cap: $2.081B, Share Price: $11.54) has received over $14 billion from Altria for a 45% stake in the company.
Another liver cancer play like DCTH, Viking Therapeutics, Inc. (VKTX) (Market Cap: $541.666M, Share Price: $7.58) a clinical-stage biopharma company focused on the development of novel therapies for metabolic and endocrine disorders announced the presentation of results from the company’s 12-week Phase 2 study of VK2809, its novel liver-selective thyroid receptor beta agonist, in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).
This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a twelve-month term consulting agreement with DCTH dated 8/31/18. The agreement calls for $40,000 in cash, and 15,000 restricted 144 shares of DCTH per month. Issuer agreed to increase monthly cash payment in September to $120,000. All payments were made directly by Delcath Systems, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. DCTH was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
Microspeculators.com Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: Regal Consulting, LLC